Literature DB >> 35739330

Analysis of Electrophysiological Mechanisms of N-Deacetyllapaconitine Monochlorhydrate, the Main Metabolite of Lappaconitine Hydrobromide.

I B Tsorin1, I Yu Teplov2, V P Zinchenko2, M B Vititnova3, E M Tsyrlina4, M S Yunusov4, S A Kryzhanovskii3.   

Abstract

In in vitro experiments on isolated rat hippocampal neurons, we studied the electrophysiological mechanisms of the antiarrhythmic effects of N-deacetyllappaconitine monochlorhydrate (DALCh), active metabolite of lappaconitine hydrobromide (allapinin). Electrical activity of neurons was recorded by the patch-clamp method in the whole cell configuration. It was shown that DALCh increased the duration of both slow and fast depolarization phases and decreased the amplitude of the action potential. DALCh effectively inhibited transmembrane currents of Na+ ions and partially K+ ions through the corresponding transmembrane voltage-gated ion channels. Thus, DALCh, in contrast to lappaconitine hydrobromide, belongs not to 1C, but to the 1A class of antiarrhythmics according to the Vaughan-Williams classification.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  K+ ion currents; Na+ ion currents; action potential; metabolite of lappaconitine hydrobromide monochlorohydrate N-deacetyllappaconitine; patch-clamp

Mesh:

Substances:

Year:  2022        PMID: 35739330     DOI: 10.1007/s10517-022-05522-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

Review 1.  [Antiarrhythmic drug allapinin: review of results of clinical investigation].

Authors:  S F Sokolov; F N Dzhakhangirov
Journal:  Kardiologiia       Date:  2002       Impact factor: 0.395

Review 2.  [Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].

Authors:  C Pott; D G Dechering; A Muszynski; S Zellerhoff; A Bittner; K Wasmer; G Mönnig; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.